Molecular interactions of cholinesterases inhibitors using in silico methods: current status and future prospects

New Biotechnology

Volumn 25, Issue 5, 2009, Pages 331-346

  Khan, Mahmud Tareq Hassan ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ACTIVE SITE; ALZHEIMER'S DISEASE; AMYLOID PROTEINS; BINDING POCKETS; BUTYRYLCHOLINESTERASE; CURRENT STATUS; FUTURE PROSPECTS; HUMAN BEING; IN-SILICO; LIVING ORGANISMS; MOLECULAR DOCKING; MOLECULAR DYNAMIC SIMULATIONS; NEURODEGENERATIVE DISORDERS; PERIPHERAL ANIONIC SITE;

BINDING SITES; BIOMARKERS; MOLECULAR DYNAMICS; PROTEINS;

X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; ALPHA VINIFERIN; ASSOANINE; BMC 0812; BMC 0814; BUTYRIC ACID; BUXAMINE B; CBC 17108IIIF; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CORONARIDINE; DECAMETHONIUM; DONEPEZIL; EDROPHONIUM; GALANTAMINE; HUPERZINE A; N ACETYLGLUCOSAMINE; OXOASSOANINE; PHYSOSTIGMINE; RIVASTIGMINE; RUPICOLINE; SANGUININE; SARSALIGNONE; TACRINE; UNCLASSIFIED DRUG; URSOLIC ACID; VAGANINE; VOACANGINE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CHOLINESTERASE INHIBITION; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME INHIBITOR INTERACTION; HUMAN; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE ALIGNMENT; SPECIES DIFFERENCE; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; AMINO ACID SEQUENCE; BINDING SITES; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; FORECASTING; HYDROPHOBICITY; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

HEXAPODA; VERTEBRATA;

EID: 67349242995     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbt.2009.03.008     Document Type: Review

References (133)

1. Clark C.M., and Karlawish J.H. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann. Intern. Med. 138 (2003) 400-410
2. Chen S., et al. Current experimental therapy for Alzheimer's disease. Curr. Neuropharmacol. 5 (2007) 127-134
3. Terry Jr. A.V., and Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 306 (2003) 821-827
4. Zhang X. Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 137-152
5. Yu B., and Hu G.Y. Donepezil blocks voltage-gated ion channels in rat dissociated hippocampal neurons. Eur. J. Pharmacol. 508 (2005) 15-21
6. Murakami K., et al. Structural basis for calcium-regulated relaxation of striated muscles at interaction sites of troponin with actin and tropomyosin. Adv. Exp. Med. Biol. 592 (2007) 71-86
7. Ramsland P.A., et al. Immunoglobulin cross-reactivity examined by library screening, crystallography and docking studies. Comb. Chem. High Throughput Screen 4 (2001) 397-408
8. Yu Q., et al. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J. Med. Chem. 42 (1999) 1855-1861
9. Yu Q.S., et al. Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase. FEBS Lett. 234 (1988) 127-130
10. Drachman D.A. Aging and the brain: a new frontier. Ann. Neurol. 42 (1997) 819-828
11. Drachman D.A., and Leber P. Treatment of Alzheimer's disease-searching for a breakthrough, settling for less. N. Engl. J. Med. 336 (1997) 1245-1247
12. Hunt R., and Taveau R.D. Br. Med. J. 2 (1906) 1788
13. Massoulie J., et al. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41 (1993) 31-91
14. Taylor P., and Radic Z. The cholinesterases: from gene to proteins. Annu. Rev. Pharmacol. Toxicol. 34 (1994) 281-320
15. Silman I., and Sussman J.L. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr. Opin. Pharmacol. 5 (2005) 293-302
16. Nachon F., et al. Butyrylcholinesterase: 3D structure, catalytic mechanisms. Ann. Pharm. Fr. 63 (2005) 194-206
17. Correa-Basurto J., et al. Docking and quantum mechanic studies on cholinesterases and their inhibitors. Eur. J. Med. Chem. 42 (2007) 10-19
18. Lindner A., et al. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J. Neurol. 244 (1997) 515-520
19. Tougu V., and Kesvatera T. Comparison of salt effects on the reactions of acetylcholinesterase with cationic and anionic inhibitors. Biochim. Biophys. Acta 1544 (2001) 189-195
20. Schwarz M., et al. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol. Ther. 67 (1995) 283-322
21. Schwarz M., et al. Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. Brain Res. Mol. Brain Res. 31 (1995) 101-110
22. Greig N.H., et al. Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr. Alzheimer Res. 2 (2005) 483-492
23. Campiani G., et al. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. J. Med. Chem. 48 (2005) 1919-1929
24. Greig N.H., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U S A 102 (2005) 17213-17218
25. Lahiri D.K., et al. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol. Scand. Suppl. 176 (2000) 60-67
26. Shen Q., et al. Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors. Eur. J. Med. Chem. 40 (2005) 1307-1315
27. Castro N.G., et al. CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline. Eur. J. Pharmacol. 580 (2008) 339-349
28. Munoz-Ruiz P., et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J. Med. Chem. 48 (2005) 7223-7233
29. Rodriguez-Franco M.I., et al. Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorg. Med. Chem. 13 (2005) 6795-6802
30. Wiesner J., et al. Acetylcholinesterases-the structural similarities and differences. J. Enzyme Inhib. Med. Chem. 22 (2007) 417-424
31. Matthews G. Neurotransmitter release. Annu. Rev. Neurosci. 19 (1996) 219-233
32. Kryger G., et al. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr. D Biol. Crystallogr. 56 Pt 11 (2000) 1385-1394
33. Bourne Y., et al. Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex. Cell 83 (1995) 503-512
34. Harel M., et al. Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. Structure 3 (1995) 1355-1366
35. Giles K., et al. Theoretical and Computational Methods in Genome Research (1997), Plenum Press pp. 303-315
36. Greenblatt H.M., et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett. 463 (1999) 321-326
37. Greenblatt H.M., et al. The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. J. Am. Chem. Soc. 126 (2004) 15405-15411
38. Harel M., et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9031-9035
39. Raves M.L., et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 4 (1997) 57-63
40. Musial A., et al. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr. Med. Chem. 14 (2007) 2654-2679
41. Blum M.M., et al. Inhibitory potency against human acetylcholinesterase and enzymatic hydrolysis of fluorogenic nerve agent mimics by human paraoxonase 1 and squid diisopropyl fluorophosphatase. Biochemistry 47 (2008) 5216-5224
42. Vaya J., and Tamir S. The relation between the chemical structure of flavonoids and their estrogen-like activities. Curr. Med. Chem. 11 (2004) 1333-1343
43. Xuereb B., et al. Cholinesterase activity in Gammarus pulex (Crustacea Amphipoda): characterization and effects of chlorpyrifos. Toxicology 236 (2007) 178-189
44. Wen H., et al. Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. Eur. J. Med. Chem. 43 1 (2008) 166-173
45. Correa-Basurto J., et al. Inhibition of acetylcholinesterase by two arylderivatives: 3a-Acetoxy-5H-pyrrolo (1,2-a) (3,1)benzoxazin-1,5-(3aH)-dione and cis-N-p-Acetoxy-phenylisomaleimide. J. Enzyme Inhib. Med. Chem. 21 (2006) 133-138
46. He X.C., et al. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B. Bioorg. Med. Chem. 15 (2007) 1394-1408
47. Kalauni S.K., et al. New cholinesterase inhibiting steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. Chem. Pharm. Bull. (Tokyo) 50 (2002) 1423-1426
48. Khalid A., et al. Structural basis of acetylcholinesterase inhibition by triterpenoidal alkaloids. Biochem. Biophys. Res. Commun. 331 (2005) 1528-1532
49. Khalid A., et al. Kinetics and structure-activity relationship studies on pregnane-type steroidal alkaloids that inhibit cholinesterases. Bioorg. Med. Chem. 12 (2004) 1995-2003
50. Khalid A., et al. Cholinesterase inhibitory and spasmolytic potential of steroidal alkaloids. J. Steroid. Biochem. Mol. Biol. 92 (2004) 477-484
51. Atta-ur-Rahman, et al. New alkaloids from Buxus sempervirens L. J. Nat. Prod. 52 (1989) 1319-1322
52. Atta Ur R., et al. New steroidal alkaloids from Fritillaria imperialis and their cholinesterase inhibiting activities. Chem. Pharm. Bull. (Tokyo) 50 (2002) 1013-1016
53. Baker D.C., et al. Mechanism of death in Syrian hamsters gavaged potato sprout material. Toxicol. Pathol. 16 (1988) 333-339
54. Giliani A.U., et al. Presence of antispasmodic, antidiarrheal, antisecretory, calcium antagonist and acetylcholinesterase inhibitory steroidal alkaloids in Sarcococca saligna. Planta Med. 71 (2005) 120-125
55. Kalauni S.K., et al. Steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. J. Nat. Prod. 64 (2001) 842-844
56. Kvaltinova Z., et al. Effect of the steroidal alkaloid buxaminol-E on blood pressure, acetylcholinesterase activity and (3H)quinuclidinyl benzilate binding in cerebral cortex. Pharmacology 43 (1991) 20-25
57. Langjae R., et al. Acetylcholinesterase-inhibiting steroidal alkaloid from the sponge Corticium sp. Steroids 72 (2007) 682-685
58. Choudhary M.I., et al. Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer's disease therapy. Biochem. Biophys. Res. Commun. 332 (2005) 1171-1177
59. Ahmad V.U., et al. Isolation of four new pterocarpans from Zygophyllum eurypterum (Syn. Z. atriplicoides) with enzyme-inhibition properties. Chem. Biodivers. 3 (2006) 996-1003
60. Atta Ur R., et al. New norditerpenoid alkaloids from Aconitum falconeri. J. Nat. Prod. 63 (2000) 1393-1395
61. Atta ur R., et al. New natural cholinesterase inhibiting and calcium channel blocking quinoline alkaloids. J. Enzyme Inhib. Med. Chem. 21 (2006) 703-710
62. Atta ur R., et al. Acetyl and butyrylcholinesterase-inhibiting triterpenoid alkaloids from Buxus papillosa. Phytochemistry 58 (2001) 963-968
63. Rahman A.U., and Choudhary M.I. Biodiversity-a wonderful source of exciting new pharmacophores. Further to a new theory of memory. Pure Appl. Chem. 74 (2002) 511-517
64. Choudhary M.I., et al. New triterpenoid alkaloid cholinesterase inhibitors from Buxus hyrcana. J. Nat. Prod. 66 (2003) 739-742
65. Choudhary M.I., et al. New cholinesterase-inhibiting triterpenoid alkaloids from Buxus hyrcana. Chem. Biodivers. 3 (2006) 1039-1052
66. Gilani A.H., et al. Presence of cholinomimetic and acetylcholinesterase inhibitory constituents in betel nut. Life Sci. 75 (2004) 2377-2389
67. Hasan A., et al. Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones. J. Enzyme Inhib. Med. Chem. 20 (2005) 41-47
68. Orhan I., et al. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J Ethnopharmacol. 91 (2004) 57-60
69. Orhan I., et al. Acetyl cholinesterase and butyrylcholinesterase inhibitory activities of some Turkish medicinal plants. J. Ethnopharmacol. 91 (2004) 57-60
70. Choudhary M.I., et al. Withanolides a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem. Biophys. Res. Commun. 334 (2005) 276-287
71. Mukherjee P.K., et al. Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother. Res. 21 (2007) 1142-1145
72. Mukherjee P.K., et al. Acetylcholinesterase inhibitors from plants. Phytomedicine 14 (2007) 289-300
73. Mukherjee P.K., et al. In vitro acetylcholinesterase inhibitory activity of the essential oil from Acorus calamus and its main constituents. Planta Med. 73 (2007) 283-285
74. Wu C.R., et al. Psoralen and isopsoralen, two coumarins of Psoraleae Fructus, can alleviate scopolamine-induced amnesia in rats. Planta Med. 73 (2007) 275-278
75. Woodruff-Pak D.S., et al. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil. Neuropsychopharmacology 32 (2007) 1284-1294
76. Villarroya M., et al. An update on the pharmacology of galantamine. Expert. Opin. Investig. Drugs 16 (2007) 1987-1998
77. Utsuki T., et al. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. J. Pharmacol. Exp. Ther. 321 (2007) 353-361
78. Kaasinen V., et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J. Clin. Psychopharmacol. 22 (2002) 615-620
79. Rahman A.U., and Choudhary M.I. Bioactive natural products as a potential source of new pharmacophores a theory of memory. Pure Appl. Chem. 73 (2001) 555-560
80. Houghton P.J., et al. Acetylcholinesterase inhibitors from plants and fungi. Nat. Product Reports 23 (2006) 181-199
81. Leonetti F., et al. Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg. Med. Chem. 16 (2008) 7450-7456
82. Berman H.M., et al. The Protein Data Bank and the challenge of structural genomics. Nat. Struct. Biol. 7 Suppl. (2000) 957-959
83. Berman H.M., et al. The Protein Data Bank. Nucleic Acids Res. 28 (2000) 235-242
84. Millard C.B., et al. Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry 38 (1999) 7032-7039
85. Dvir H., et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry 41 (2002) 10810-10818
86. Dvir H., et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 Å resolution: kinetic and molecular dynamic correlates. Biochemistry 41 (2002) 2970-2981
87. Doucet-Personeni C., et al. A structure-based design approach to the development of novel, reversible AChE inhibitors. J. Med. Chem. 44 (2001) 3203-3215
88. Bartolucci C., et al. Back door" opening implied by the crystal structure of a carbamoylated acetylcholinesterase. Biochemistry 38 (1999) 5714-5719
89. Nicolet Y., et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 278 (2003) 41141-41147
90. Millard C.B., et al. Reaction products of acetylcholinesterase and VX reveal a mobile histidine in the catalytic triad. J. Am. Chem. Soc. 121 (1999) 9883-9884
91. Nachon F., et al. Structural data on the aging of diethylphosphoryl-butyrylcholinesterase. Chem. Biol. Interact. 157-158 (2005) 408-409
92. Nachon F., et al. Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. Biochemistry 44 (2005) 1154-1162
93. Bartolucci C., et al. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819). J. Med. Chem. 49 (2006) 5051-5058
94. Rydberg E.H., et al. Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. J. Med. Chem. 49 (2006) 5491-5500
95. Ngamelue M.N., et al. Crystallization and X-ray structure of full-length recombinant human butyrylcholinesterase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 63 Pt 9 (2007) 723-727
96. Xie Q., et al. Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J. Med. Chem. 51 (2008) 2027-2036
97. Grigoryan H.A., et al. alpha,beta-Dehydrophenylalanine choline esters, a new class of reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase. Chem. Biol. Interact. 171 (2008) 108-116
98. Sauvaitre T., et al. New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series. J. Med. Chem. 50 (2007) 5311-5323
99. Piazzi L., et al. Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J. Med. Chem. 50 (2007) 4250-4254
100. Odzak R., et al. Evaluation of monoquaternary pyridinium oximes potency to reactivate tabun-inhibited human acetylcholinesterase. Toxicology 233 (2007) 85-96
101. Law K.S., et al. Dialkyl phenyl phosphates as novel selective inhibitors of butyrylcholinesterase. Biochem. Biophys. Res. Commun. 355 (2007) 371-378
102. Kwon Y.E., et al. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Bioorg. Med. Chem. 15 (2007) 6596-6607
103. Haviv H., et al. Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors. Curr. Top. Med. Chem. 7 (2007) 375-387
104. Gani O.A., et al. Theoretical calculatons of the catalytic triad in short chain alcohol dehydrogenases/reductases. Biophys. J. 94 4 (2008) 1412-1427
105. da Silva C.H., et al. Virtual screening, molecular interaction field, molecular dynamics, docking, density functional, and ADMET properties of novel AChE inhibitors in Alzheimer's disease. J. Biomol. Struct. Dyn. 24 (2007) 515-524
106. Alcaro S., et al. Molecular modelling and enzymatic studies of acetylcholinesterase and butyrylcholinesterase recognition with paraquat and related compounds. SAR QSAR Environ. Res. 18 (2007) 595-602
107. Xie Q., et al. Investigation of the binding mode of (-)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method. J. Mol. Model 12 (2006) 390-397
108. Rollinger J.M., et al. Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia × soulangiana. J. Nat. Prod. 69 (2006) 1341-1346
109. Lushington G.H., et al. Acetylcholinesterase: molecular modeling with the whole toolkit. Curr. Top. Med. Chem. 6 (2006) 57-73
110. da Silva C.H., et al. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease. J. Mol. Graph. Model 25 (2006) 169-175
111. Carotti A., et al. Ester derivatives of annulated tetrahydroazocines: a new class of selective acetylcholinesterase inhibitors. Bioorg. Med. Chem. 14 (2006) 7205-7212
112. Alisaraie L., and Fels G. Molecular docking study on the 'back door' hypothesis for product clearance in acetylcholinesterase. J. Mol. Model 12 (2006) 348-354
113. Akula N., et al. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA. Bioorg. Med. Chem. Lett. 16 (2006) 6277-6280
114. Malone D.M., and Lindesay J. Cholinesterase inhibitors and cardiovascular disease: a survey of old age psychiatrists' practice. Age Ageing 36 (2007) 331-333
115. Masuda Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease-from basic research to bedside. Curr. Alzheimer Res. 1 (2004) 315-321
116. Ballard C., et al. High prevalence of neurovascular instability in neurodegenerative dementias. Neurology 51 (1998) 1760-1762
117. Ballard C.G., et al. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr. Cogn. Disord. 10 (1999) 97-103
118. Leach A.R., et al. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J. Med. Chem. 49 (2006) 5851-5855
119. Shoichet B.K., et al. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6 (2002) 439-446
120. Shoichet B.K., et al. Hits, leads and artifacts from virtual and high-throughput screening. Molecular Informatics: Confronting Complexity. May 13th-16th, 2002 (2002)
121. Moitessier N., et al. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br. J. Pharmacol. 153 Suppl. 1 (2008) S7-26
122. Borman S. Drugs by design. Chem. Eng. News 83 (2005) 28-30
123. Khan M.T., et al. Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays. J. Med. Chem. 52 1 (2009) 48-61
124. Tumiatti V., et al. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. J. Med. Chem. 47 (2004) 6490-6498
125. Rampa A., et al. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]aminoalkoxyheteroar yl derivatives. J. Med. Chem. 41 (1998) 3976-3986
126. Sousa S.F., et al. Protein-ligand docking: current status and future challenges. Proteins 65 (2006) 15-26
127. Beene D.L., et al. Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry 41 (2002) 10262-10269
128. Zacharias N., and Dougherty D.A. Cation-pi interactions in ligand recognition and catalysis. Trends Pharmacol. Sci. 23 (2002) 281-287
129. Imai Y.N., et al. Propensities of polar and aromatic amino acids in noncanonical interactions: nonbonded contacts analysis of protein-ligand complexes in crystal structures. J. Med. Chem. 50 (2007) 1189-1196
130. Ravelli R.B., et al. Static Laue diffraction studies on acetylcholinesterase. Acta Crystallogr. D Biol. Crystallogr. 54 Pt 6 Pt 2 (1998) 1359-1366
131. Feldman H., et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001) 613-620
132. Potkin S.G., et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol. 4 (2001) 223-230
133. Rockwood K., et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. J. Neurol. Neurosurg. Psychiatry 71 (2001) 589-595